-
Mashup Score: 0
This burgeoning world of life science advancements has awakened investors’ interest with its financial and healthcare potential.
Source: www.forbes.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 5New platform solves key problems in targeted drug delivery - 5 month(s) ago
Research potentially removes barriers for promising cell and gene therapies
Source: news.northwestern.eduCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 30Non-coding RNAs in disease: from mechanisms to therapeutics - Nature Reviews Genetics - 5 month(s) ago
In this Review, the authors describe our current knowledge of the role of microRNAs, long non-coding RNAs and circular RNAs in disease, with a focus on cardiovascular, neurological, infectious diseases and cancer. Further, they discuss the potential use of non-coding RNAs as disease biomarkers and as therapeutic targets.
Source: www.nature.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 0
Mayo Clinic has completed a genomic database of over 100,000 patients for precision medicine and predictive analytics. The Tapestry research study was completed
Source: www.beckershospitalreview.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0
Researchers used Pharma Proteomics Project plasma protein profiles for UK Biobank participants to identify genetic associations with protein levels, providing disease clues.
Source: www.genomeweb.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Data-driven Healthcare Startup Answer Genomics Raises $500K from Inflection Point Ventures - 7 month(s) ago
Hyper-personalized & data driven wellness platform, Answer Genomics has raised $500K in a pre-series A Round from Inflection Point Ventures. The
Source: www.indianweb2.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Precision Medicine Navigators May Increase Genomic Testing Rates Among Black Patients With Prostate Cancer - The ASCO Post - 7 month(s) ago
The presence of precision medicine navigators may increase the likelihood that patients with prostate cancer, especially Black patients, will receive genomic testing that may help predict the severity of their disease and guide treatment, according to findings presented by Allen et al at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 122). Black patients are 76% more likely to be diagnosed w ith prostate cancer and 120% more likely to die from the disease than White
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma - 7 month(s) ago
PURPOSE To determine the genetic predisposition underlying pancreatic acinar cell carcinoma (PACC) and characterize its genomic features. METHODS Both somatic and germline analyses were performed using an Food and Drug Administration–authorized matched tumor/normal sequencing assay on a clinical cohort of 28,780 patients with cancer, 49 of whom were diagnosed with PACC. For a subset of PACCs, whole-genome sequencing (WGS; n = 12) and RNA sequencing (n = 6) were performed. RESULTS Eighteen of 49 (36.7%) PACCs harbored germline pathogenic variants in homologous recombination (HR) and DNA damage response (DDR) genes, including BRCA1 (n = 1), BRCA2 (n = 12), PALB2 (n = 2), ATM (n = 2), and CHEK2 (n = 1). Thirty-one PACCs displayed pure, and 18 PACCs harbored mixed acinar cell histology. Fifteen of 31 (48%) pure PACCs harbored a germline pathogenic variant affecting HR-/DDR-related genes. BRCA2 germline pathogenic variants (11 of 31, 35%) were significantly more frequent in pure PACCs than
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 7Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma - 7 month(s) ago
PURPOSE To determine the genetic predisposition underlying pancreatic acinar cell carcinoma (PACC) and characterize its genomic features. METHODS Both somatic and germline analyses were performed using an Food and Drug Administration–authorized matched tumor/normal sequencing assay on a clinical cohort of 28,780 patients with cancer, 49 of whom were diagnosed with PACC. For a subset of PACCs, whole-genome sequencing (WGS; n = 12) and RNA sequencing (n = 6) were performed. RESULTS Eighteen of 49 (36.7%) PACCs harbored germline pathogenic variants in homologous recombination (HR) and DNA damage response (DDR) genes, including BRCA1 (n = 1), BRCA2 (n = 12), PALB2 (n = 2), ATM (n = 2), and CHEK2 (n = 1). Thirty-one PACCs displayed pure, and 18 PACCs harbored mixed acinar cell histology. Fifteen of 31 (48%) pure PACCs harbored a germline pathogenic variant affecting HR-/DDR-related genes. BRCA2 germline pathogenic variants (11 of 31, 35%) were significantly more frequent in pure PACCs than
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Personalized Biomarker-Based Umbrella Trial in Recurrent or Metastatic HNSCC - The ASCO Post - 7 month(s) ago
In a Korean phase II trial (KCSG HN 15-16 TRIUMPH) reported in the Journal of Clinical Oncology, Keam et al described results of a personalized biomarker-driven umbrella trial for the treatment of patients with platinum-refractory recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) using matched molecular targeted agents. In the multicenter trial, targeted next-generation sequencing was performed between October 2017 and August 2020 in 203 patients. Patients were assigned to treatment
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Council Post: What Advances In #Genomics Tech May Mean For Investors https://t.co/oWc727HLmU